Gene: CSNK1D

1453
ASPS|CKIdelta|FASPS2|HCKID
casein kinase 1 delta
protein-coding
17q25.3
Ensembl:ENSG00000141551 MIM:600864 Vega:OTTHUMG00000178601 UniprotKB:P48730
NG_012828.1
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.316e-1 (AD)  1.919e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg11439535chr17:80203277CSNK1DGene body1.332e-4Alcohol use disorders26763658
cg27455640chr17:80202345CSNK1D3'UTR3.735e-4Alcohol use disorders26763658
cg26103512chr17:80231812CSNK1D6.500e-8Smoking27651444
cg20493718chr17:80202979CSNK1D1.390e-8Alcohol consumption per day27843151
cg15117681chr17:80202426CSNK1D2.590e-8Alcohol consumption der day27843151
cg21369801chr17:80202961CSNK1D2.480e-9Alcohol consumption der day27843151
cg26103512chr17:80231812CSNK1D2.650e-8Smoking28686328

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
RNF400.963
RIC8A0.958
AAMP0.957
PSMD30.951
AP3D10.95
CCAR20.949
VCP0.948
RAB1B0.948
HGS0.946
SSRP10.942

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.776
OR4F29-0.735
MTRNR2L6-0.31
MTRNR2L9-0.294
MTRNR2L10-0.267
CTNNA3-0.246
SH2D1A-0.238
OR6C74-0.23
KLRB1-0.227
FMO3-0.222

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0164032,4-dinitrotoluene"2,4-dinitrotoluene affects the expression of CSNK1D mRNA"21346803
C0212962-ethoxyethanol2-ethoxyethanol results in increased expression of CSNK1D mRNA19643169
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSNK1D mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSNK1D mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of CSNK1D mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of CSNK1D mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of CSNK1D mRNA17562736
D000082AcetaminophenAcetaminophen results in increased expression of CSNK1D mRNA17585979
D000082Acetaminophen[Clofibrate co-treated with Acetaminophen] affects the expression of CSNK1D mRNA17585979
D000082AcetaminophenPPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CSNK1D mRNA]17585979
D000108Acetylcarnitine[Acetylcarnitine co-treated with NGF protein] results in increased expression of CSNK1D mRNA14654561
D000643Ammonium ChlorideAmmonium Chloride affects the expression of CSNK1D mRNA16483693
D018501Antirheumatic AgentsAntirheumatic Agents affects the expression of CSNK1D mRNA24449571
D001151ArsenicArsenic affects the methylation of CSNK1D gene25304211
C006632arsenic trioxidearsenic trioxide results in increased expression of CSNK1D mRNA20458559
C015001arsenitearsenite results in increased expression of CSNK1D mRNA18191166
D001280AtrazineAtrazine results in increased expression of CSNK1D mRNA25929836
D001280AtrazineAtrazine results in increased expression of CSNK1D mRNA22378314
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of CSNK1D mRNA22300585
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of CSNK1D mRNA"19150397
C006780bisphenol Abisphenol A results in decreased expression of CSNK1D mRNA29275510
C006780bisphenol Abisphenol A affects the expression of CSNK1D mRNA25181051
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of CSNK1D mRNA15336504
D020111Chlorodiphenyl (54% Chlorine)Chlorodiphenyl (54% Chlorine) results in decreased expression of CSNK1D mRNA23650126
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CSNK1D gene20938992
D002994ClofibrateClofibrate results in decreased expression of CSNK1D mRNA16081524
D002994ClofibrateClofibrate affects the expression of CSNK1D mRNA17585979
D002994Clofibrate[Clofibrate co-treated with Acetaminophen] affects the expression of CSNK1D mRNA17585979
D002994ClofibratePPARA affects the reaction [[Clofibrate co-treated with Acetaminophen] affects the expression of CSNK1D mRNA]17585979
C018021cobaltous chloridecobaltous chloride results in increased expression of CSNK1D mRNA19376846
D003513CycloheximideCycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA]11007951
D016572CyclosporineCyclosporine results in increased expression of CSNK1D mRNA20106945|2556210
D003561CytarabineCytarabine results in decreased expression of CSNK1D mRNA21198554
D003976DiazinonDiazinon affects the expression of CSNK1D mRNA22546817
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of CSNK1D mRNA26924002
D004026DieldrinDieldrin affects the expression of CSNK1D mRNA22546817
C024629dimethyl phthalatedimethyl phthalate affects the expression of CSNK1D mRNA26924002
D052244Endocrine DisruptorsEndocrine Disruptors results in increased expression of CSNK1D mRNA25198161
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CSNK1D gene20938992
C039281furanfuran results in increased methylation of CSNK1D gene22079235
D005839GentamicinsGentamicins results in increased expression of CSNK1D mRNA22061828
C010176halofuginonehalofuginone results in increased expression of CSNK1D mRNA17180598
D006861Hydrogen PeroxideHydrogen Peroxide results in decreased secretion of CSNK1D mRNA21179422
C411652IC 261IC 261 results in increased expression of CSNK1D protein16027726
C411652IC 261IC 261 results in decreased activity of CSNK1D protein16027726
D015759Ionomycin[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSNK1D mRNA25613284
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of CSNK1D gene20938992
C005219methyl cellosolvemethyl cellosolve results in increased expression of CSNK1D mRNA19643169
C002950methylformamidemethylformamide affects the expression of CSNK1D mRNA17040096
C002950methylformamidemethylformamide analog affects the expression of CSNK1D mRNA17040096
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of CSNK1D mRNA23179753|2627250
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CSNK1D mRNA"27188386
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of CSNK1D mRNA"20188158
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium affects the expression of CSNK1D mRNA12710931
D009532NickelNickel results in increased expression of CSNK1D mRNA24768652|2558310
C022838nickel chloridenickel chloride results in decreased expression of CSNK1D mRNA17312168
C022838nickel chloridenickel chloride affects the expression of CSNK1D mRNA22546817
C042670N-vinyl-2-pyrrolidinone[N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1D mRNA22037397
D010100OxygenOxygen deficiency results in increased expression of CSNK1D mRNA20880076
C568608PCI 5002[PCI 5002 co-treated with Zinc] results in increased expression of CSNK1D mRNA18593933
D010634PhenobarbitalPhenobarbital results in increased expression of CSNK1D mRNA22037397
C432165pyrazolanthronepyrazolanthrone results in decreased activity of CSNK1D protein12534346
D011720PyrazolesPyrazoles analog results in decreased activity of CSNK1D protein12534346
D011743PyrimidinesPyrimidines analog results in decreased activity of CSNK1D protein12534346
C104586roscovitineroscovitine results in decreased activity of CSNK1D protein12534346
C513635S-2-pentyl-4-pentynoic hydroxamic acidS-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of CSNK1D mRNA21427059
C017947sodium arsenitesodium arsenite affects the expression of CSNK1D mRNA19590694
C017947sodium arsenitesodium arsenite results in increased expression of CSNK1D mRNA22714537
D000952Antigens, Polyomavirus Transforming"Antigens, Polyomavirus Transforming results in decreased expression of CSNK1D mRNA"26680231
D013749TetrachlorodibenzodioxinCycloheximide promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA]11007951
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of CSNK1D mRNA11007951
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of CSNK1D mRNA21570461|2468072
D013755Tetradecanoylphorbol Acetate[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSNK1D mRNA25613284
C009495titanium dioxidetitanium dioxide results in increased expression of CSNK1D mRNA27760801
C012589trichostatin Atrichostatin A affects the expression of CSNK1D mRNA28542535
C015559trimellitic anhydridetrimellitic anhydride results in increased expression of CSNK1D mRNA19042947
D014415TunicamycinTunicamycin results in increased expression of CSNK1D mRNA17127020
D014520UrethaneUrethane results in increased expression of CSNK1D mRNA28818685
C406224valdecoxibvaldecoxib results in decreased expression of CSNK1D mRNA24136188
D014635Valproic AcidValproic Acid affects the expression of CSNK1D mRNA25979313
D014635Valproic AcidValproic Acid results in increased methylation of CSNK1D gene29154799
D014635Valproic AcidValproic Acid affects the expression of CSNK1D mRNA17292431
D014635Valproic AcidValproic Acid results in decreased expression of CSNK1D mRNA20546886|2142705
C034028vanadyl sulfatevanadyl sulfate results in increased expression of CSNK1D mRNA16330358
C025643vinclozolinvinclozolin affects the expression of CSNK1D mRNA19015723
C025643vinclozolinvinclozolin results in decreased expression of CSNK1D mRNA23034163
D014810Vitamin EVitamin E results in decreased expression of CSNK1D mRNA19244175
D014874Water Pollutants, Chemical"Water Pollutants, Chemical results in increased expression of CSNK1D mRNA"25198161
D015032Zinc[PCI 5002 co-treated with Zinc] results in increased expression of CSNK1D mRNA18593933

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004672protein kinase activity-IDA16618118  
GO:0004672protein kinase activity-ISS-  
GO:0004672protein kinase activity-TAS8786104  
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-IDA25500533  
GO:0004674protein serine/threonine kinase activity-TAS-  
GO:0005515protein binding-IPI16189514  16618118  20708156  21179498  22609948  25416956  
GO:0005524ATP binding-IEA-  
GO:0042277peptide binding-IEA-  
GO:0045296cadherin binding-HDA25468996  
GO:0050321tau-protein kinase activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000086G2/M transition of mitotic cell cycle-TAS-  
GO:0001934positive regulation of protein phosphorylation-IMP20412773  
GO:0006468protein phosphorylation-IDA16618118  
GO:0006468protein phosphorylation-ISS-  
GO:0007020microtubule nucleation-IMP24648492  
GO:0007030Golgi organization-IMP24648492  
GO:0010389regulation of G2/M transition of mitotic cell cycle-TAS-  
GO:0016055Wnt signaling pathway-IEA-  
GO:0018105peptidyl-serine phosphorylation-IBA21873635  
GO:0018105peptidyl-serine phosphorylation-IDA25500533  
GO:0032436positive regulation of proteasomal ubiquitin-dependent protein catabolic process-ISS-  
GO:0032922circadian regulation of gene expression-ISS-  
GO:0034067protein localization to Golgi apparatus-IMP24648492  
GO:0042752regulation of circadian rhythm-ISS-  
GO:0048208COPII vesicle coating-TAS-  
GO:0051225spindle assembly-IDA10826492  
GO:0061512protein localization to cilium-IMP24648492  
GO:0071539protein localization to centrosome-IMP24648492  
GO:0090263positive regulation of canonical Wnt signaling pathway-IMP20412773  
GO:0097711ciliary basal body-plasma membrane docking-TAS-  
GO:1905426positive regulation of Wnt-mediated midbrain dopaminergic neuron differentiation-IC-  
GO:1905515non-motile cilium assembly-IMP24648492  
GO:1990090cellular response to nerve growth factor stimulus-IEA-  
GO:2000052positive regulation of non-canonical Wnt signaling pathway-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000139Golgi membrane-IEA-  
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-ISS-  
GO:0005654nucleoplasm-TAS-  
GO:0005737cytoplasm-IBA21873635  
GO:0005794Golgi apparatus-IDA10826492  
GO:0005813centrosome-IDA21399614  21422228  
GO:0005819spindle-IDA10826492  
GO:0005829cytosol-TAS-  
GO:0005876spindle microtubule-IDA10826492  
GO:0005886plasma membrane-IDA16027726  
GO:0033116endoplasmic reticulum-Golgi intermediate compartment membrane-TAS-  
GO:0043005neuron projection-IEA-  
GO:0048471perinuclear region of cytoplasm-IDA16027726  
KEGG ID KEGG Term
hsa04340Hedgehog signaling pathway
hsa04540Gap junction
hsa04710Circadian rhythm
Reactome ID Reactome Term Evidence
R-HSA-1640170Cell CycleTAS
R-HSA-1852241Organelle biogenesis and maintenanceTAS
R-HSA-199977ER to Golgi Anterograde TransportTAS
R-HSA-199991Membrane TraffickingTAS
R-HSA-204005COPII-mediated vesicle transportTAS
R-HSA-2565942Regulation of PLK1 Activity at G2/M TransitionTAS
R-HSA-380259Loss of Nlp from mitotic centrosomesTAS
R-HSA-380270Recruitment of mitotic centrosome proteins and complexesTAS
R-HSA-380284Loss of proteins required for interphase microtubule organization from the centrosomeTAS
R-HSA-380287Centrosome maturationTAS
R-HSA-380320Recruitment of NuMA to mitotic centrosomesTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-400253Circadian ClockIEA
R-HSA-446203Asparagine N-linked glycosylationTAS
R-HSA-453274Mitotic G2-G2/M phasesTAS
R-HSA-5617833Cilium AssemblyTAS
R-HSA-5620912Anchoring of the basal body to the plasma membraneTAS
R-HSA-5653656Vesicle-mediated transportTAS
R-HSA-597592Post-translational protein modificationTAS
R-HSA-6791226Major pathway of rRNA processing in the nucleolus and cytosolTAS
R-HSA-68877Mitotic PrometaphaseTAS
R-HSA-68886M PhaseTAS
R-HSA-69275G2/M TransitionTAS
R-HSA-69278Cell Cycle, MitoticTAS
R-HSA-72312rRNA processingTAS
R-HSA-8854518AURKA Activation by TPX2TAS
R-HSA-8868773rRNA processing in the nucleus and cytosolTAS
R-HSA-8953854Metabolism of RNATAS
R-HSA-948021Transport to the Golgi and subsequent modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28296937Effects of circadian clock genes and health-related behavior on metabolic syndrome in a Taiwanese population: Evidence from association and interaction analysis. (2017)Lin EPLoS One